Redeye is positive that GenesisCare expands the preferred network for DigniCap systems to include locations in the US. This expansion comes after an agreement was already made with GenesisCare in Australia at the end of 2020. GenesisCare has an extensive worldwide network of integrated oncology care, and we have hopes that this expansion will continue throughout the network. We view this news as another sign of the DigniCap Delta system's value to both patients and providers. At this point, we are not adjusting our estimates, even though the positive bias that we saw in the Q4 report continues. We reiterate our motivated value of SEK 15 per share in our base case.